Bristol-Myers Squibb Co — AI technical analysis, September 2026
NYSE/NASDAQ · Pharmaceuticals
AI Recommendation
HOLD
Technical score 70/100
Last price: $63.73 · 52W range $42.52 – $68.64
Short answer
Should you buy BMY right now? Stockgaide's AI rates BMY as
HOLD, with a technical score of
70/100 at a last price of $63.73.
The 50-day average is above the 200-day average, and RSI sits at 31.1.
Wall Street's consensus rating is 2.43/5.
Full AI analysis for BMY
Strategic Conclusion
Recommendation: Hold
Why? BMY trades near its 52-week high with a solid long-term uptrend (SMA50 > SMA200), but near-term momentum has weakened — RSI at 31.1 and MACD below its signal line suggest a pullback may continue. Valuation is undemanding at 14.2x P/E with a high 4.58% dividend, but the mixed technical picture and a consensus leaning toward “hold” argue for patience rather than aggressive buying.
Ideal profile: Long-term dividend investors already holding; new buyers should wait for a better entry.
Price range: Entry zone around $60–$62; upside target $68–$70; stop-loss below $58 for traders.
Practical action: Hold existing positions. For new money, wait for a dip toward $61 or a clear MACD bullish crossover before initiating.
1. Recent Price & Momentum
Current price $64.10 is 6.6% below the 52-week high ($68.64) and 50.7% above the low ($42.52) — clearly in the upper portion of its 12-month range.
The stock is not at the top but is within striking distance; the recent slide from ~$68 toward $64 has brought RSI to oversold-ish levels.
Short-term scenario: likely to consolidate between $62 and $66. A break above $66 could retest $68.64; a break below $62 would open the door to $58–$60.
2. Valuation (P/E)
P/E TTM of 14.17 is below the typical pharma sector average (around 16–18), suggesting the stock is not overvalued.
The price already reflects modest growth expectations; the high dividend yield (4.58%) provides a valuation floor, but upside re-rating depends on pipeline/news catalysts.
RSI(14) at 31.1 is approaching oversold — a bounce is possible, but momentum is not confirming yet.
MACD (0.1785) is below its signal line (0.7990) with negative histogram (-0.6205) — bearish short-term momentum.
Technical score: 70/100 (BUY) due to the moving-average structure, but this is offset by weak short-term momentum signals.
4. Analyst Consensus
Mean rating 2.43/5 corresponds to a “Hold/Buy” — 15 buy, 18 hold, 2 sell.
Analysts are moderately positive but not enthusiastic, aligning with the technical picture: long-term uptrend, short-term caution. The consensus does not strongly support a fresh buy at current levels.
Technical signal details
Rule-based read from price and momentum indicators only — the score behind the AI's recommendation above. Technical score: 70/100 (BUY).
50-day moving average is above the 200-day — medium-term uptrend (golden-cross territory).
MACD is below its signal line — bearish momentum.
RSI at 31.07 — neutral momentum.
Wall Street consensus rating of 2.43 — moderately positive.
Stockgaide's AI currently rates BMY as HOLD, with a technical score of 70 out of 100 at a last price of $63.73. This is educational content, not investment advice.
Is BMY in an uptrend?
BMY's 50-day moving average (63.55) is above its 200-day moving average (58.58), which points to a medium-term uptrend.
What is BMY's RSI today?
BMY has a 14-day RSI of 31.1, which places it in neutral territory (above 70 is overbought, below 30 is oversold).
What do analysts say about BMY?
Wall Street analysts covering BMY have a consensus rating of 2.43 out of 5 (1 = Strong Buy), meaning they are moderately positive — 15 Buy · 18 Hold · 2 Sell.
Where is BMY trading in its 52-week range?
BMY last traded at $63.73, against a 52-week range of $42.52 to $68.64 — about 81% of the way up that range.
Get the full AI analysis of BMY
Price targets, fundamentals deep-dive and an AI-written report — free, no signup.